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Abstract
Background:  Polymorphisms of the human prion protein gene (PRNP) contribute to the genetic
determinants of Creutzfeldt-Jakob disease (CJD). Numerous polymorphisms in the promoter regions as
well as the open reading frame of PRNP were investigated. Greater than 90% of Korean, Chinese, and
Japanese carry the homozygote 129 MM codon. In Korea, polymorphisms have not been comprehensively
studied, except codons 129 and 219 in PRNP among Korean CJD cases. Although polymorphisms at
codons 129 and 219 play an important role in susceptibility to sporadic CJD, patients with other
polymorphisms in PRNP exhibited critical distinctions of clinical symptoms.
Methods: The genetic analyses of PRNP were carried out among probable CJD patients in comparison
with the results from magnetic resonance imaging (MRI) and electroencephalogram (EEG).
Results: The molecular analyses revealed that three mutations at codons D178N, E200K, and M232R in
heterozygosity. Patients with the D178N and M232R mutations had a 129MM codon, whereas the patient
with the E200K mutation showed 129MV heterozygosity. They all revealed strong 14-3-3 positive signals.
The 67-year-old patient with the D178N-129M mutation showed progressive gait disturbance and
dysarthria was in progress. The 58-year-old patient with the E200K mutation coupled to the 129MV codon
had gait disturbance, dysarthria, agitation, and ataxic gait, and progressed rapidly to death 3 months from
the first onset of symptoms. The 65-year-old patient with the M232R mutation showed rapidly progressive
memory decline and gait disturbance, and died within 16 months after onset of symptoms.
Conclusion: Despite differences in ethnicity, the clinical and pathological outcomes were similar to the
respective mutations around the world, except absence of insomnia in D178N-129M subject.
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Background
Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-
Scheinker syndrome (GSS) fatal familial insomnia (FFI),
and Kuru are transmissible spongiform encephalopathies
(TSE) diseases in human. TSEs are typically fatal neurode-
generative diseases; 90% of CJD patients die within 1 year
of diagnosis which occurs sporadically at an annual inci-
dence of 1 per million populations [1,2]. Among all CJD
cases, 10–15% has been reported as autosomal dominant
disorders, with mutations in the prion protein gene
(PRNP) on chromosome 20, and is categorized as genetic
TSE. These reports have suggested the importance of PRNP
mutations in familial CJD (fCJD). PRNP mutations have
been discovered from more than 30 sites, and lead to
amino-acid substitutions, premature stop codons, or the
insertion of additional octapeptide repeats at the N-termi-
nus [3]. Some could be transmitted in an autosomal dom-
inant inheritance pattern, with nearly 100% penetrance
[4,5]. These findings emphasize the importance of inves-
tigating  PRNP  polymorphisms or mutations to predict
disease occurrence.
As a rapidly progressing neurodegenerative disorder, the
symptoms of CJD are characterized by progressive demen-
tia, ataxia, and myoclonus [6]. Familial CJD tends to have
an earlier age of onset and longer duration than sporadic
CJD (sCJD). The E200K mutation is the most common in
fCJD (more than 70% worldwide) with the D178N muta-
tion being the second most frequent [7]. The effect of
codon 129 on the phenotype associated with the E200K
mutation seems to be less distinguishable than for the
D178N mutation [8]. Hence, the phenotypic effect of the
D178N mutation depends on polymorphism at codon
129 of PRNP. Fatal familial insomnia (FFI) seems to be
associated with a D178N mutation and methionine at
codon 129 of PRNP, whereas the phenotype of sCJD was
observed for the D178N mutation with valine at codon
129 [9]. The D178N mutation almost never indicated the
characteristic electroencephalogram (EEG) changes, but
this was not the case when it was linked with the E200K
mutation [1].
The clinical, EEG and neuroimaging features in patients
with E200K-129M mutation were similar to sCJD. A typi-
cal EEG, with periodic spike and wave (PSW) complexes,
was observed in about 75% of all patients [10]. The levels
of 14-3-3 protein in the cerebrospinal fluid (CSF)
increased in almost all cases [11]. The phenotype of
patients with E200K-129V mutations was similar to that
of patients categorized as CJD VV2 type. The typical pre-
senting symptom was ataxia followed by myoclonus and
PSW complexes on EEG [12].
The M232R mutation was reported in eight Japanese
patients without any previous family history of neurode-
generative diseases [13]. The clinical feature of M232R
mutation was similar to that of sCJD. Common symp-
toms were progressive memory impairment, gait distur-
bance, and myoclonus, and a typical EEG with PSW
complexes was observed in all cases except in an 84-year-
old subject [14].
CJD is clinically diagnosed with specific finding with mag-
netic resonance imaging (MRI), periodic sharp and wave
complexes (PSWCs), and elevated 14-3-3 protein in the
CSF [15-17]. The detection of 14-3-3 protein in CSF is an
important marker supporting the diagnosis of CJD
[16,18]. Although the positive detection of 14-3-3 protein
has been reported in other neurological disorders [19],
the diagnostic criteria of the World Health Organization
(WHO) for CJD includes 14-3-3 detection [20].
In this study, the mutations of PRNP at codons 178, 200-
129, and 232 reported in other countries were first discov-
ered among probable CJD patients in Korea. In addition,
the level of 14-3-3 protein released into the CSF was stud-
ied and compared with the MRI/EEG results.
Methods
Patient history
The clinical findings of probable CJD patients in Korea are
summarized in Table 1.
Case 1
A 67-year-old man was admitted to hospital because of
progressive gait disturbance and dysarthria. He didn't
have family history of similar problems. The subject also
had extrapyramidal symptoms such as rigidity and brady-
kinesia, but no sign was evident of myoclonus, visual
symptoms, pyramidal symptoms, or cognitive impair-
ment. The cerebellar function test was conducted by tan-
dem gait, heel-to-shin, finger-to-nose, and rapid
alternating movements, and the results were normal. The
laboratory findings for electrolytes, antibodies of the thy-
roid gland, liver function test, immunological test for
syphilis, and viral markers were negative. His CSF was
clear and colorless without any white blood cells. A few
months after onset the patient's health deteriorated grad-
ually into akinetic mutism, which progressed further.
Case 2
A 58-year-old man was hospitalized with gait disturbance
and confused mentality, and there was no family history.
He had fallen from a bike 2 weeks prior to his visit to hos-
pital. He had stumbled, could not walk in a straight line,
and frequently fell down. He presented with a history of
chronic alcoholism and hypertension. His symptoms pro-
gressed and his condition deteriorated, with dysarthria
and agitation. He could not perform the high cortical
function test due to reduced attention, and he developed
an ataxic gait. Although he looked cautious during the
neuropsychological test, he showed frequent disorienta-BMC Infectious Diseases 2009, 9:132 http://www.biomedcentral.com/1471-2334/9/132
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tion and confusion, and often fell into a stupor. He was
not able to be woken from sleep on the 6th day after hos-
pitalization, and on the 12th day developed aspiration
pneumonia, which was treated. He later developed myo-
clonic movements in his limbs. The laboratory findings
for electrolytes, antibodies of the thyroid gland, liver func-
tion test, immunological test for syphilis, and viral mark-
ers were negative. His CSF was clear and colorless without
any white blood cells. He died 3 months after the first
onset of neurological signs of CJD.
Case 3
A 65-year-old man presented with rapidly progressive
memory decline and gait disturbance. He had no known
diabetes, cardiac disease, or previous stroke except hyper-
tension. Also, he had no family history of dementia or
overseas travel, he was alert. Cranial nerve, sensory, reflex,
cerebellar function, and motor power examinations did
not revealed any abnormality. But he showed a bilateral
swaying gait. The cognitive function test showed frontal
lobe dysfunction, and his mini-mental state examination
score was 22. His rating score for clinical dementia was
0.5, and his Barthel index was 14. The laboratory findings
for electrolytes, antibodies of the thyroid gland, liver func-
tion test, immunological test for syphilis, and viral mark-
ers were negative. His CSF was clear and colorless without
any white blood cells. His symptom progressed further
and he died within 16 months after onset of symptoms.
Samples
Blood and CSF samples were collected from 99 probable
CJD patients in Korea. Genetic analyses of their PRNP
sequences revealed mutations at D178N-129M, E200K-
129MV, M232R, 129MV, E219K, E219K-129MV, P102L,
and V180I. Among them, further analyses were carried out
on three patients with mutations at D178N-129M,
E200K-129MV, and M232R under their consents for
research only. Control DNA was obtained for analysis
from healthy volunteers. This study was approved by the
Institutional Review Board (IRB).
Western blotting
A recombinant 14-3-3β plasmid cloned into the expres-
sion vector pEF6/V5-His TOPO was transiently trans-
fected into 293T cells using FuGENE 6 (Roche Applied
Sciences, Basel, Switzerland). The CSF (32 μl) from prob-
able CJD patients were separated on a 4–12% Bis-Tris gel,
then transferred to a PVDF (polyvinylidene fluoride)
membrane, followed by 5% dry milk. Polyclonal antibod-
ies specific to 14-3-3β (Santa Cruz Biotechnology, sc-629)
were used for blotting. The signals were developed using a
SuperSignal®  West Pico Chemiluminescent Substrate
(PIERCE, IL, USA). CSF from definite sCJD patient was
used as the positive control.
DNA preparation and sequence analysis
Genomic DNA of probable CJD patients was extracted
from 200 μl blood samples using the QIAamp DNA Blood
Mini Kit (Qiagen), following the manufacturer's protocol.
Polymerase chain reaction (PCR) was performed with the
S13 (5'-AAGCCTGGAGGATGGAACAC-3') and T2 (5'-
CCCACTATCAGGAAGATGAG-3') primers, which ampli-
fied nucleotide 79–758 of PRNP. The 30 cycles of PCR
were performed as follows: 94°C for 1 min, 60°C for 45
sec, and 72°C for 1 min 30 sec. PCR products for sequenc-
ing were purified using a Gel Extraction Kit (Qiagen, MD,
USA). DNA sequencing with primers, S13 and T2, was car-
ried out using a BigDye® Terminator v3.1 Cycle Sequenc-
ing Kit (Applied Biosystems) on an ABI PRISM 3730xl
DNA Analyzer (Applied Biosystems, CA, USA). Results of
DNA sequencing were analyzed using Sequencing Analy-
sis Software (Applied Biosystems, CA, USA).
SNaPshot (Single Nucleotide Primer Extension) assay
SNaPshot was analyzed with the SNaPshot Multiplex Kit
according to the ABI protocol, using PCR products ampli-
Table 1: The clinical findings of probable CJD patients in Korea with codons 178, 200-129, and 232 mutations.
Patient Case 1 Case 2 Case 3
Age of onset 67 58 65
Mutation D178N-129M E200K-129MV M232R
Sex M M M
Symptoms of onset Progressive gait disturbance
Dysarthria
Extrapyramidal sign
Gait disturbance
Confused mentality
Dysarthria
Agitation
Myoclonus
Memory decline
Gait disturbance
Total clinical duration Alive (27 months)* 3 months 16 months
MRI imaging
(DWI or FLAIR)
High signal intensities in both 
parietal and occipital gyri
High signal intensity on bilateral 
frontotemporoparietal area and caudate 
nucleus
High signal intensities from the cortex of 
the parieto-occipital and the temporal 
lobes
EEG finding Normal Sharp or spike and slow waves Diffuse theta to delta range slow waves
14-3-3 protein in CSF Positive Positive Positive
* As of May 2008BMC Infectious Diseases 2009, 9:132 http://www.biomedcentral.com/1471-2334/9/132
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fied under the same conditions as for DNA sequencing
(Applied Biosystems, CA, USA). SNaPshot primers were
S178 (5'-TTGATTGTGATATTGACGCAGT-3') for the
codon 178 variants, S129 (5'-GTGGTGGGGGGCCTT-
GGCGGCTAC-3') for the codon 129 variants, S200 (5'-
AAAAAAAAAACCACCAAGGGGGAGAACTTCACC-3') for
the codon 200 variants, and S232 (5'-TATTACCAGAGAG-
GATCGAGCA-3') for the codon 232 variants. The samples
were analyzed on an ABI PRISM® 3100 Genetic Analyzer
(Applied Biosystems, CA, USA), and the data were ana-
lyzed with GeneScan software (Applied Biosystems, CA,
USA).
Routine restriction fragment length polymorphism (RFLP)
Each PCR products amplified using the same condition as
for the DNA sequencing for Cases 1 and 2, were digested
with the restriction enzymes Tth111 I, Nsp I, and BsmA I
(New England Biolabs). The PCR conditions for Case 3
were as follows: 30 cycles of 94°C for 30 sec, 60°C for 1
min, and 72°C for 1 min with the K-7 (5'-GTCAC-
CACAACCACCAAGGG-3') and K-8 (5'-CAGGAAGACCT-
TCCTCATCC-3') primers. The PCR products for Case 3
were then digested with Nla III (New England Biolabs,
Hitchin, UK). The resulting fragments were separated by
electrophoresis on a 10% TBE gel (Bio-Rad Ready Gel),
and stained and visualized using EtBr.
Results
Detection of the 14-3-3 protein in CSF samples from 
probable CJD patients
In the Western blot of the 14-3-3 protein, band from the
293T cells transfected with 14-3-3β expression plasmid
matched exactly the bands from the CSF of the positive
control and probable CJD patients, confirming the bands
from probable CJD patients as 14-3-3. The 14-3-3
appeared to have slight signal in the CSF of negative con-
trol, which was obtained from a patient with Japanese
encephalitis virus (JEV). Later, this patient was diagnosed
as normal. The detected levels of 14-3-3 in CSF from Cases
1, 2, and 3 were similar, although mutated codons in
PRNP were different (Figure 1).
DNA sequencing analysis and SNaPshot
After amplifying and sequencing PRNP  from genomic
DNA of probable CJD patients in Korea, three PRNP
mutations were found (Figure 2A). In Case 1, a single base
substitution at codon 178, from GAC to AAC, was found
for the amino acid mutation from Asp to Asn. In Case 2,
two point mutations were discovered: GAG to AAG (Glu
to Lys) at codon 200, and ATG to GTG (Met to Val) at
codon 129. Case 3 had one point mutation at codon
232(ATG to AGG), resulting Met replacement with Arg. As
shown in the electrophotograms (Figure 2A), two overlap-
ping peaks for the heterozygotes were observed in Cases 1,
2, and 3 patients, in contrast to the homozygote peaks for
the healthy control. To confirm the DNA sequencing
results in Figure 2A, a SNaPshot assay was performed with
the PCR products of PRNP from Cases 1, 2, and 3 (Figure
2B). The PCR products from patients with mutations con-
firmed two peaks, in comparison to a single peak from the
healthy control. Two black and red peaks at codon 178
represented heterozygotes of Asp and Asn, while only one
peak appeared in homozygotes. Four peaks were apparent
in Case 2 since two codons in PRNP, at 200 and 129,
could be translated to heterozygotes in probable CJD
patients. The two peaks for codon 129 (indicated with
arrows) were heterozygotes for Met and Val, and the sec-
ond set of two peaks was from the heterozygotes for Glu
and Lys. The heterozygotes at codon 232 for Case 3 repre-
sented two peaks of Met and Arg (Figure 2B). Both Case 1
and Case 3 showed Met/Met in codon 129, and the other
PRNP mutations and polymorphisms were not found in
Cases 1, 2, and 3 (data not shown).
RFLP
The results from RFLP with a different batch of PRNP PCR
products from DNA sequencing and SNaPshot assay veri-
fied the three PRNP mutations. In Case 1, the mutation at
codon 178 abolished digestion with Tth111 I. Conversion
of one allele to Asn presented a band of 680 bp, while
RFLP from the healthy control showed two bands of 223
and 456 bp, respectively (Figure 2C). PCR products from
the healthy control yielded bands of 75, 296, and 309 bp
after Nsp I digestion, while mutation at codon 129 in Case
2 had an additional band of 384 bp. The bands of 296 and
309 bp were not differentiated due to limitation in the
separation of fragments with similar size in the DNA gel.
In addition, after incubating the PCR products with BsmA
I, the digestion site disappeared for the mutation at codon
200 fragment in Case 2. BsmA I digestion of the wild type
PCR products at codon 200 yielded two fragments (167
Increased 14-3-3 was observed in CSF from probable CJD  patients using immunoblot Figure 1
Increased 14-3-3 was observed in CSF from probable 
CJD patients using immunoblot. CSF from healthy con-
trol and probable CJD patients were compared with 293T 
cell transfected with the pEF6/V5-His plasmid encoding 14-3-
3β, and the CSF of a definite sCJD patient as positive control.BMC Infectious Diseases 2009, 9:132 http://www.biomedcentral.com/1471-2334/9/132
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and 513 bp, respectively), while the codon 200 variant
yielded fragments of 167, 513, and 680 bp (Figure 2C). In
Case 3, Nla III digested the wild type PCR products into
two fragments, of 129 and 83 bp, respectively. The AGG
substitution at codon 232 abolished the Nla III digestion
site in the PCR products, yielding a full-sized 212 bp frag-
ment (Figure 2C). The result of RFLP was tantamount to
that of DNA sequencing and SNaPshot.
MRI and EEG
In Case 1, lacunar infarctions appeared in the pons, left
thalamus, and both putamen and cerebral white matter.
Diffuse cerebral atrophy was more prominent in the fron-
toparietal lobes. Some high signal intensities were
observed along gyri of both parietal and occipital lobes in
diffusion and fluid-attenuated inversion-recovery (FLAIR)
images (Figure 3A). For EEG analysis, 32 channel digital
EEG monitoring was performed with the patient in an
awake state. The posterior dominant rhythm was less well
regulated with 8~9 Hz activity, which was reactive to eye
opening. There was no definite interictal epileptiform dis-
charge or focal slowing, and the patient was diagnosed as
normal EEG (data not shown).
In Case 2, the diffusion-weighted MRI (DWI) showed
higher signal intensities in the left side than the right side
of basal ganglia or the cerebral cortex (Figure 3A). After 50
days, the second MRI revealed higher signal intensities in
the right side of the cerebral cortex than the left, indicating
damage to the right hemisphere of the brain. The follow-
Mutations in PRNP were detected from probable CJD patients Figure 2
Mutations in PRNP were detected from probable CJD patients. Electropherogram of the DNA sequences (A), SNaP-
shot assay (B), and digested PCR fragments with restriction enzymes as indicated (C) revealed the mutations at D178N 
(GAC→AAC), E200K (GAG→AAG)-129MV (ATG→GTG), and M232R (ATG→AGG). (A) Arrow heads indicate the 
mutated nucleotide peaks. (B) The x and y axes represented the size of bases and the fluorescence intensities, respectively. 
The color of each peak indicates the identity of the ddNTPs in the primer extension reaction, emitting specific fluorescences 
according to ddNTP; Green/A, Black/C, Blue/G, and Red/T. The orange peaks represented the internal size standard. The 
arrows labeled "129" or "200" indicate SNaPshot products resulting from the extensions of the S129 and S200 primers, respec-
tively.BMC Infectious Diseases 2009, 9:132 http://www.biomedcentral.com/1471-2334/9/132
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CJD profiles of MRI and EEG from probable CJD patients Figure 3
CJD profiles of MRI and EEG from probable CJD patients. (A) Brain MRIs of Cases 1, 2, and 3 with PRNP polymor-
phisms. The two images at the top and bottom left are of Case 1 with the D178N-129M mutation; the two images at center 
are of Case 2 with the E200K-129MV mutation; and the two images at top and bottom right are of Case 3 with M232R muta-
tion. The top three are DWI images and the bottom three are T2-FLAIR images. The white arrow indicates a lesion with a high 
signal. (B) EEG of Case 2 (left panel) and Case 3 (right panel). The EEG of Case 1 was normal (data not shown).BMC Infectious Diseases 2009, 9:132 http://www.biomedcentral.com/1471-2334/9/132
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up FLAIR images indicated atrophy in the right frontal
lobes and caudate nucleus (Figure 3A). Frequent general-
ized rhythmical (0.5~1.5 Hz) slow activities were
observed, which consisted of sharp or spike and slow
waves with very high amplitude, more from the left cere-
bral hemisphere (Figure 3B).
In Case 3, DWI showed high signal intensities mainly
from the cortex of the parieto- occipital and temporal
lobes, and FLAIR images showed high signal intensity
lesion from the cortex of temporal lobe (Figure 3A). The
EEG results revealed slow waves ranging from diffuse
theta to delta (Figure 3B).
Discussion and Conclusion
The genotype of the patients seemed to play an important
role in the pathogenesis of CJD. The D178N mutation
abolished the salt bridge between the conserved residues
Asp-178-Arg-164, suggesting that the mutant protein had
reduced thermodynamic stability [21]. Moreover, Asp-
178 was in the vicinity of the disulfide bridge (S-S), and
mutation in this region could potentially interfere with
the formation of disulfide bridge, and potentially cause
protein aggregation [22]. The E200K mutation indicated a
significant reduction in glycosylation in comparison to
the wild-type, which could affect to the conformational
changes in prion protein [23]. An analogous reduction in
glycosylation was reported in fCJD patients with the
E200K mutation [24]. Codon 232 at the carboxy-terminal
region in the PrP was implicated in post-translational
modification by the glycosylphosphatidylinositol anchor
during protein maturation [25]. It seemed that arginine
substitution for methionine at codon 232 prohibited the
cleavage during the glycosylphosphatidylinositol anchor
biosynthetic process, resulting in conformational changes
in mutant PrP [12].
The D178N mutation with 129MM was the genotype for
FFI and sCJD with 129MV or 129VV [26]. Japanese CJD
patients with the D178N mutation with 129MM did not
have clinical insomnia [27], whereas Chinese patients
with same genotype were diagnosed with typical FFI [28].
Furthermore, D178N didn't show only FFI phenotype all
the time in case of not only Asia but also Europe, but
sometimes showed CJD phenotype which shows pheno-
typic variability [29]. The Korean patient with the D178N
mutation with 129MM had a similar phenotype to the
Japanese CJD patients, so we suggest that other potential
factors may be related to the clinical features. The symp-
toms of the patient with the M232R mutation was similar
to those of Japanese CJD patients with the M232R muta-
tion [12]. The patient is considered a slow type of patients
with M232R, due to not showing akinetic mutism or
PSWC [30]. Despite differences in ethnicity, the clinical
and pathological outcomes were similar to the respective
mutations around the world. Autopsies were not per-
formed in all cases, since the Korean tended to avoid in
performing autopsies due to the traditional Confucianism
culture. Therefore, we need a development substitute
diagnostic method and we consider that a clinical view of
DWI and FLAIR imaging may be useful in the early pre-
mortem diagnosis of CJD.
The D178N-129M, E200K-129MV, and M232R muta-
tions, which were previously reported from other coun-
tries, were identified for the first time among probable
CJD patients in Korea. Diverse PRNP polymorphisms in
the Korean population will be investigated in the future.
PRNP polymorphisms among Korean, Chinese, and Japa-
nese populations will provide insights into the associa-
tions between polymorphisms, CJD susceptibilities, and
their clinical phenotypic variations, especially when
129MM codon has been reported to be a dominant deter-
minant in more than 90% of populations.
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